Guthrie S - Search Results

1

Epidemiology of AL amyloidosis: a real-world study using US claims data.

Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Quock TP, et al. Among authors: guthrie s. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. Blood Adv. 2018. PMID: 29748430 Free PMC article.

2

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium.

Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Lousada I, et al. Among authors: guthrie s. Adv Ther. 2015 Oct;32(10):920-8. doi: 10.1007/s12325-015-0250-0. Epub 2015 Oct 23. Adv Ther. 2015. PMID: 26498944 Free PMC article.

3

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. Gertz MA, et al. Among authors: guthrie sd. J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8. J Clin Oncol. 2016. PMID: 26858336 Free PMC article. Clinical Trial.

4

Light Chain (AL) Amyloidosis: The Journey to Diagnosis.

McCausland KL, White MK, Guthrie SD, Quock T, Finkel M, Lousada I, Bayliss MS. McCausland KL, et al. Among authors: guthrie sd. Patient. 2018 Apr;11(2):207-216. doi: 10.1007/s40271-017-0273-5. Patient. 2018. PMID: 28808991 Free PMC article.

5

Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data.

Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Quock TP, et al. Among authors: guthrie s. J Comp Eff Res. 2018 Jun;7(6):549-559. doi: 10.2217/cer-2017-0100. Epub 2018 Feb 2. J Comp Eff Res. 2018. PMID: 29390860 Free article.

6

Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis.

McCausland KL, Quock TP, Rizio AA, Bayliss MS, White MK, Guthrie SD, Sanchorawala V. McCausland KL, et al. Among authors: guthrie sd. Br J Haematol. 2019 Jun;185(5):998-1001. doi: 10.1111/bjh.15693. Epub 2018 Nov 22. Br J Haematol. 2019. PMID: 30467849 Free article. No abstract available.

7

Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis.

Rizio AA, White MK, McCausland KL, Quock TP, Guthrie SD, Yokota M, Bayliss MS. Rizio AA, et al. Among authors: guthrie sd. Am Health Drug Benefits. 2018 Nov;11(8):430-437. Am Health Drug Benefits. 2018. PMID: 30647830 Free PMC article.

8

The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data.

Reddy SR, Chang E, Tarbox MH, Broder MS, Tieu RS, Guthrie S, Vera-Llonch M, Pollock MR. Reddy SR, et al. Among authors: guthrie s. Neurol Ther. 2020 Dec;9(2):473-482. doi: 10.1007/s40120-020-00194-4. Epub 2020 May 25. Neurol Ther. 2020. PMID: 32451849 Free PMC article.

9

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.

Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, Liedtke M, Sanchorawala V, Schönland S, Wechalekar A, Zonder JA, Palladini G, Walling J, Guthrie S, Nie C, Karp C, Jin Y, Kinney GG, Merlini G. Gertz MA, et al. Among authors: guthrie s. Blood. 2023 Oct 5;142(14):1208-1218. doi: 10.1182/blood.2022019406. Blood. 2023. PMID: 37366170 Free PMC article. Clinical Trial.

10

The burden of amyloid light chain amyloidosis on health-related quality of life.

Bayliss M, McCausland KL, Guthrie SD, White MK. Bayliss M, et al. Orphanet J Rare Dis. 2017 Jan 19;12(1):15. doi: 10.1186/s13023-016-0564-2. Orphanet J Rare Dis. 2017. PMID: 28103898 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

371 results

Search Page